Opexa Therapeutics, Inc.
http://www.opexatherapeutics.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Opexa Therapeutics, Inc.
Korean Bioventure Financing Continues Downward Spiral In Q3
VC Investment in South Korea’s biopharma sector drops again as investors continue to shy away amid higher interest rates and reduced out-licensing deals.
Unity Looks Ahead To Pivotal Study With Positive DME Data For UBX1325
The company announced 24-week results from the Phase II BEHOLD trial in diabetic macular edema patients already treated with anti-VEGF therapy, showing gains in a tough population.
Finance Watch: 3T Biosciences Emerges With $40m And Novel TCR Platform
Private Company Edition: Westlake Village BioPartners’ latest launch 3T Biosciences also licensed a second TCR platform from Stanford University. In other recent financings, Senda raised a $123m series C round, Orna revealed a $221m series B and CPRIT funded several cancer drug developers.
Deal Watch: Ovid Teams With Gensaic On Phage-Derived, Gene-Delivered Therapies
Plus deals involving Glaukos/iVeena, Daré/Hennepin Life Sciences, Prevail/Lacerta, Chugai/Noile-Immune, Horizon/Q32, EpiAxis/Peptilogics and more.